What iLoF does

iLoF is a UK-headquartered digital health company founded in 2020 that operates an AI-powered, photonics-based platform for non-invasive patient screening and stratification in clinical trials. The core product is a cloud-based library of optical fingerprints — proprietary phenotypic signatures generated by shining light on microlitre-scale blood samples and applying AI to the resulting optical signals. The platform is described as label-free, target-agnostic, and capable of producing results in under 10 seconds without consumables, with published value claims of 40% cost savings and 70% time savings on patient screenings. Lead applications focus on Alzheimer's disease, with extensions into COVID-19 severity forecasting and Ovarian Cancer subtype stratification.

The business model is enterprise B2B, with iLoF selling screening and stratification services to global pharmaceutical, biotech, and clinical research organizations through a direct field sales motion. Pricing is quote-based and not publicly disclosed, and engagements are described as adapted to each clinical trial's protocol. The company operates three offices — London (HQ), New York (North America sales), and Porto (engineering/R&D) — with 11-50 employees. Notable partners include the Global Alzheimer's Platform Foundation, where iLoF contributes to the Bio-Hermes-002 observational study alongside Sanofi, Biogen, Eli Lilly, and Roche.

iLoF has raised approximately $10.5M in disclosed equity and grant funding across at least eight capital events from 2019 to 2025, including a $4.1M seed round led by Faber in July 2022 with M12 (Microsoft's venture fund) participating, a ~$2.68M European Innovation Council grant in 2023, and later strategic investments from Hamamatsu Ventures and Lince Capital. The leadership team comprises three co-founders (Luis Valente, CEO; Mehak Mumtaz, COO; Paula Sampaio, CSO) supported by advisors with senior executive experience at Microsoft, Google, Disney, and Amazon, plus photonics and digital health regulatory expertise. Public recognition includes CB Insights' most promising Digital Health companies list and Financial Times' Transformational Business in Healthcare designation.

Name

iLoF

Legal name

iLoF

Website

https://ilof.tech

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

iLoF is a UK-based digital health company (founded 2020) operating an AI-powered photonics platform that generates optical fingerprints from blood samples to non-invasively stratify patients for pharmaceutical and biotech clinical trials.

Ownership category

akta.pro rank

Product category

AI-powered digital health drug discovery platform

NAICS

Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• AI drug discovery
• Patient stratification platform
• Clinical trial screening
• Optical biomarker analysis
• Photonics biosensing

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Screening and Stratification Services: iLoF provides a blood-based screening test that stratifies patients for clinical trials, offering pharmaceutical and biotech clients patient screening services. The platform is adapted to each clinical trial's needs, suggesting a subscription or service-based model with per-test or per-screening pricing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

iLoF provides an AI-powered cloud platform that combines photonics and machine learning to convert small biological samples into optical fingerprints used as phenotypic signatures. Its blood-based screening test stratifies patients for clinical trials, removing heterogeneity due to underlying pathophysiology, disease stage or progression. Services are adapted to each clinical trial's needs and target pharmaceutical, biotech, and clinical research customers worldwide.

Product overview

iLoF offers a unified platform architecture centered on its AI-powered iLoF Platform, which comprises a cloud-based library of optical fingerprints combined with the iLoF Method for blood-based patient screening. The platform integrates photonics and AI to collect optical signals that convert biological samples into phenotypic signatures, enabling non-invasive tracking, screening, and stratification for personalized drug discovery and clinical trial optimization.

Differentiator

Problem solved

Functional benefit

Products and services

• iLoF Platform A cloud-based library of optical fingerprints powered by photonics and AI that provides non-invasive tracking, screening and stratification of patients in drug discovery, adapted to each clinical trial's needs. Used by pharmaceutical, biotech and clinical research organizations.
• iLoF Method A blood-based screening test that stratifies patients for clinical trials, removing heterogeneity due to underlying pathophysiology, disease stage or degree of progression. Requires only microlitres of blood and produces results in under 10 seconds without consumables. Delivered to pharmaceutical, biotech and clinical research customers.

Quantifiable outcome

• 40% cost savings on patient screenings
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Global pharmaceutical, biotech, and clinical firms (unnamed collaborations)coreStrategic or Co-development Partner · 1 July 2022iLoF raised $4.1 million in seed funding in July 2022 with the explicit aim of accelerating collaborations with global pharmaceutical, biotech, and clinical firms to enhance personalized drug discovery using AI technology. These collaborations involve using iLoF's platform for patient screening and stratification in clinical trials.
• Global Alzheimer's Platform Foundation (GAP)coreStrategic or Co-development PartneriLoF is listed as a contributing partner in the Global Alzheimer's Platform Foundation's Bio-Hermes-002 observational study, which evaluates blood-based and digital biomarkers alongside imaging to improve prediction, detection, and diagnosis of Alzheimer's disease. GAP's Bio-Hermes-002 study involves pharmaceutical partners including Sanofi, Biogen, Eli Lilly, Roche, and others, with data stored on the AD Workbench platform from the Gates Ventures Alzheimer's Disease Data Initiative.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Tempus AI: Tempus is a large AI-driven precision medicine platform that combines molecular data, clinical data, and AI to support pharma R&D, clinical trial design, and patient stratification. It overlaps with iLoF on the AI-for-clinical-trial-stratification use case, though its data modality (multi-omics) and scale are much broader than iLoF's photonic-optical fingerprint approach.
• SOPHiA Genetics: SOPHiA Genetics offers an AI-powered platform that analyzes complex genomic and multimodal patient data to support cancer and rare disease clinical research. It serves pharma and clinical research customers with data-driven patient insights, overlapping iLoF's clinical trial stratification mission but using sequencing rather than photonic-optical data.
• Exscientia: Exscientia is an AI-driven pharma company that combines AI drug design with patient-derived data to prioritize and design clinical candidates. It shares iLoF's pharma-focused AI-for-drug-discovery positioning, though its emphasis is on compound design rather than blood-based screening for trial stratification.
• Recursion Pharmaceuticals: Recursion combines high-throughput wet-lab experimentation with AI-driven phenotypic screening to discover and develop new therapeutics. It overlaps with iLoF in the AI-enabled phenotypic screening space, but operates at a much larger scale with proprietary lab automation rather than photonic-optical fingerprinting.
• Schrödinger: Schrödinger provides a physics-based computational platform for molecular simulation and drug discovery, sold to pharma and biotech. It addresses a related but distinct step in the pharma R&D workflow versus iLoF's trial stratification focus, but shares the AI/ML-for-pharma enterprise GTM motion.

Direct peers

• Owkin: Owkin is an AI biotech that builds patient stratification and outcome-prediction models from multimodal patient data for pharma clinical trials. Like iLoF, it sells AI tools to pharma and biotech to improve trial design and drug development, with comparable GTM and customer base.
• CytoReason: CytoReason is an AI company that builds computational disease models from multi-omics and clinical data to support pharma drug development and trial stratification. Like iLoF, it sells AI-driven patient insights to pharma R&D teams and competes for similar enterprise budgets.

Emerging players

• Aignostics: Aignostics applies AI to pathology and multi-modal patient data to support pharma biomarker discovery and clinical trial patient selection. It overlaps with iLoF's clinical trial stratification mission but uses histology/pathology rather than photonic-optical signals.
• Lantern Pharma: Lantern Pharma uses AI and genomic data to identify responders and guide precision oncology drug development. It shares iLoF's AI-enabled patient stratification thesis in oncology but is more vertically integrated into drug development.
• C2i Genomics: C2i Genomics provides AI-driven liquid-biopsy-based minimal residual disease (MRD) detection to support cancer clinical trials and treatment monitoring. Like iLoF, it uses blood-based biomarkers with AI to support pharma clinical trials, but focuses specifically on oncology MRD rather than multi-disease stratification.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

• Xx.com/iLoF_tech

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds12 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iLoF